#9319. Pentoxifylline for treatment of major depression after percutaneous coronary intervention or coronary artery bypass grafting: A randomized, double-blind, placebo-controlled trial

November 2026publication date
Proposal available till 17-05-2025
4 total number of authors per manuscript6020 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Clinical Psychology;
Psychiatry and Mental Health;
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
2510 $1340 $1170 $1000 $
Contract №9319.1 Contract №9319.2 Contract №9319.3 Contract №9319.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

Abstract:
Near one-fifth of patients with coronary artery disease (CAD) develop major depressive disorder (MDD), an independent risk factor of mortality in these patients. We investigated the efficacy of oral pentoxifylline in treating MDD in CAD patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in a 6-week trial.
Keywords:
Antidepressants; Cardiovascular disease; Depressive disorder; Pentoxifylline; Phosphodiesterase inhibitors

Contacts :
0